Many cancers exhibit high levels of the reverse transcriptase enzyme. Single-agent lamivudine, a reverse transcriptase inhibitor, stopped disease progression in over 25% of patients with fourth-line refractory metastatic colorectal cancer. These results provide evidence for the evaluation of reverse transcriptase inhibitors as a new class of anti-cancer drugs.